Pargluva Effective But Cardiovascular Risks Difficult to Assess, FDA Reviewers Say

Drug Industry Daily
KEYWORDS FDA / NDA
A A

FDA scientists believe Bristol-Myers Squibb (BMS) and Merck’s co-developed diabetes treatment Pargluva is effective, but concerns remain about whether the drug candidate poses cardiovascular risks, according to FDA briefing documents released Sept. 8.

To View This Article:

Login

Subscribe To Drug Industry Daily